Champions Oncology, Inc.
CSBR
$5.26
-$0.20-3.66%
NASDAQ
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -16.45% | 10.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.45% | 10.14% | |||
| Cost of Revenue | -22.91% | 21.65% | |||
| Gross Profit | -9.06% | -0.62% | |||
| SG&A Expenses | -3.72% | 13.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.27% | 12.77% | |||
| Operating Income | -178.61% | -201.08% | |||
| Income Before Tax | -108.86% | -192.94% | |||
| Income Tax Expenses | 309.52% | 133.33% | |||
| Earnings from Continuing Operations | -139.07% | -217.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -139.07% | -204.10% | |||
| EBIT | -178.61% | -201.08% | |||
| EBITDA | -229.87% | -71.59% | |||
| EPS Basic | -138.31% | -203.61% | |||
| Normalized Basic EPS | -231.34% | -148.55% | |||
| EPS Diluted | -138.31% | -203.61% | |||
| Normalized Diluted EPS | -231.34% | -150.76% | |||
| Average Basic Shares Outstanding | 0.19% | 0.69% | |||
| Average Diluted Shares Outstanding | 0.19% | -3.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||